These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23789291)

  • 21. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?
    Pitoia F; Degrossi OJ; Niepomniszcze H
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):924; author reply 924-5. PubMed ID: 15034676
    [No Abstract]   [Full Text] [Related]  

  • 23. [Radioactive iodine therapy of metastasizing colloid struma; radioiodine therapy of carcinoma of the thyroid gland].
    PAOLINO W; ZAMBELLI E
    Minerva Med; 1952 Aug; 43(63-64):198-205. PubMed ID: 13012927
    [No Abstract]   [Full Text] [Related]  

  • 24. [Radioiodine therapy of thyroid carcinoma].
    EICHLER O; HESS H; LINDER F; SCHMEISER K
    Langenbecks Arch Klin Chir Ver Dtsch Z Chir; 1951; 269(1):19-36. PubMed ID: 14869113
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy.
    Lau WF; Zacharin MR; Waters K; Wheeler G; Johnston V; Hicks RJ
    Intern Med J; 2006 Sep; 36(9):564-70. PubMed ID: 16911548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.
    Elias AN; Lizotte P
    Clin Nucl Med; 2006 Sep; 31(9):517-9. PubMed ID: 16921272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma.
    Coelho SM; Vaisman F; Buescu A; Mello RC; Carvalho DP; Vaisman M
    Braz J Med Biol Res; 2011 Jan; 44(1):73-7. PubMed ID: 21085896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioiodine in the treatment of metastatic thyroid carcinoma.
    SEIDLIN SM
    Med Clin North Am; 1952 May; 36(3):663-80. PubMed ID: 14928848
    [No Abstract]   [Full Text] [Related]  

  • 29. The evolving use of radioiodine therapy in differentiated thyroid cancer.
    Mayson SE; Yoo DC; Gopalakrishnan G
    Oncology; 2015; 88(4):247-56. PubMed ID: 25503797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine.
    Singh B; Bollmann R; Ahmadzadehfar H; Biersack HJ; Ezziddin S
    Br J Radiol; 2006 Sep; 79(945):e84-7. PubMed ID: 16940367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conventional withdrawal of thyroid hormone before radioiodine therapy in differentiated thyroid carcinoma: how frequently are adequately raised TSH levels attained?
    McLaughlin CM; Hunter SJ; Bell PM; McCance DR; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):169-70. PubMed ID: 18042175
    [No Abstract]   [Full Text] [Related]  

  • 32. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
    Bulotta S; Celano M; Costante G; Russo D
    Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of radioiodine therapy on urinary iodine excretion.
    Meller B; Lauer I; Bähre M; Richter E
    Nuklearmedizin; 1998 May; 37(3):107-12. PubMed ID: 9604231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
    Berg G; Lindstedt G; Suurküla M; Jansson S
    J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma.
    Löffler M; Weckesser M; Franzius C; Kies P; Schober O
    Nuklearmedizin; 2003 Dec; 42(6):240-3. PubMed ID: 14668956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.
    Mihailovic J; Stefanovic L; Malesevic M; Markoski B
    Thyroid; 2009 Mar; 19(3):227-32. PubMed ID: 19265493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood radioiodine concentration and blood radiation dosage during I131 therapy for metastatic thyroid carcinoma.
    SEIDLIN SM; YALOW AA; SIEGEL E
    J Clin Endocrinol Metab; 1952 May; 12(9):1197-1204. PubMed ID: 12981154
    [No Abstract]   [Full Text] [Related]  

  • 38. The treatment of thyroid cancer with radioiodine (I-131).
    FOSTER CG
    Int Rec Med Gen Pract Clin; 1952 Jun; 165(6):361-3. PubMed ID: 14945913
    [No Abstract]   [Full Text] [Related]  

  • 39. [On the treatment of thyroid cancer and its metastases with radioiodine 131].
    CLOSUIT M; LAPP R; LERCH P
    Helv Med Acta; 1951 Oct; 18(4-5):469-74. PubMed ID: 14873181
    [No Abstract]   [Full Text] [Related]  

  • 40. The use of thiouracil in the treatment of metastatic carcinoma of the thyroid with radioiodine.
    RALL JE; MILLER WN; FOSTER CG; PEACOCK WC; RAWSON RW
    J Clin Endocrinol Metab; 1951 Nov; 11(11):1273-80. PubMed ID: 14880607
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.